A quorum was present and Dr. James De Muth, Chair, presided over the General Chapters–Dosage Forms Expert Committee (GCDF EC) face-to-face meeting. The following is a summary of the actions and key discussion topics that impacted the work of the GCDF EC, grouped by topic.

1. **Chinese Salicylic Acid Qualification Tablet**: EC members received a presentation on a new dissolution method published in the latest edition of the *Chinese Pharmacopoeia*. EC members approved a motion that USP should investigate setting scientific standards for appropriately sized equipment for dissolution to meet the needs of dosage forms.

2. **General Chapter <1> Injections**: EC members received an update on the status of this approved revision that became official May 1, 2016. EC members approved a motion to reevaluate <1> later in the cycle to see if additional revisions are needed.

3. **General Chapter <905> Uniformity of Dosage Units**: EC members received an update on the status of the <905> revision. EC members approved a motion to accept the most recent <905> draft submission for the Pharmacopeial Discussion Group.

4. **Joint Subcommittee on Solubility**: EC members agreed to explore formation of a Joint Subcommittee to develop an informational general chapter on solubility.

5. **Subcommittee, Joint Subcommittees, and Expert Panels**: EC members received updates from the following Subcommittees, Joint Subcommittees, and Expert Panels:
   - <785> Osmolality and Osmolarity Expert Panel
   - <1790> Visual Inspection of Injections Expert Panel
   - <788> Particulate Matter in Injections Expert Panel
   - <909> Uniformity of Dose from Oral Suspensions in Multi-Unit Containers Joint Subcommittee
   - Nanotechnology Joint Subcommittee
   - Subcommittee A: Performance Verification Testing
   - Subcommittee B: <2040> Disintegration and Dissolution of Dietary Supplements
   - Solubility Criteria for Veterinary Drugs Expert Panel
   - Subcommittee C: <1151> Pharmaceutical Dosage Forms
   - Subcommittee D: <1004> Mucosal Products—Product Performance Tests
   - Subcommittee E: <3> Topical and Transdermal Drug Products—Quality Tests
   - Subcommittee H: <1090> Assessment of Drug Product Performance—Bioavailability, Bioequivalence, and Dissolution
   - Subcommittee I: Aerosols
     - <5> Inhalation and Nasal Drug Products—General Information and Product Quality Tests
     - <601> Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers
Spacers & Valved Holding Chambers Used with Inhalation Aerosols
Data Analysis for Orally Inhaled and Nasal Products
- Subcommittee J: Foams
- Subcommittee M: Oral Drug Products–Product Quality Tests
- Use of Enzymes in the Dissolution Testing of Gelatin Capsules Expert Panel
- Viscosity – Rheology Subcommittee

6. **Subcommittees**: The EC formed the following Subcommittees:
   - <701> Disintegration
   - <729> Globule Size Distribution in Lipid Injectable Emulsions
   - <1711> Dissolution Procedures for Oral Dosage Forms
   - <1217> Tablet Breaking Force

7. **Joint Subcommittees**: EC members will be part of the following Joint Subcommittees
   - Gummies Nomenclature Joint Subcommittee
   - Solubility Joint Subcommittee
   - Content Uniformity Joint Subcommittee

8. **Sutures Expert Panel**: EC members agreed to the formation of a Sutures Expert Panel
to review the following General Chapters:
   - <861> Sutures Diameter
   - <871> Sutures – Needle Attachment
   - <881> Tensile Strength